🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT07214311
Recruiting Phase 2/3

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

NCT07214311 · tracked via the Priya Life Science UK tracker
Sponsor
Peptilogics
Phase
Phase 2/3
Started
2026-02-03
Last updated
2026-09-14

Condition(s) studied

Prosthetic-joint Infection

Investigational drug(s) / intervention(s)

PLG0206Placebo

PLG0206: PLG0206 Solution

Placebo: Placebo

Study summary

The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure.

Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female participants age between 18 and \<80 years * Able to provide informed consent, geographically stable, and able to comply with the required follow-up visits * Suspected or confirmed PJI of the knee * Well-fixed and positioned prosthesis and good condition of surrounding soft tissue (no sinus tract) * A single DAIR procedure is indicated as treatment of PJI * Agree to use contraceptives if of childbearing potential Exclusion Criteria: * Loose prosthesis or surgical treatment planned for removal of well-fixed, nonmodular implants * Anticipated to require antibiotic therapy for \>6 months after DAIR procedure * Infection spread beyond the affected knee joint (e.g., osteomyelitis) * History of a prior PJI of the affected knee * Two or more prior revisions in the affected joint * Epithelialized sinus tract with evidence of communication to the joint or visualization of prosthesis * Diabetes mellitus and with an A1c ≥9% * History of malignant disease and having received immunosuppressive therapy, radiation therapy, or chemotherapy within the past year * Known immunodeficiency (e.g., splenectomy; sickle cell anemia; human immunodeficiency virus \[HIV\] with recent CD4 count \<200 cells/mm3; or primary humoral, bone marrow, or other transplantation)

Primary outcome measure(s)

Trial sites (17)

FacilityCityRegionStatus
Clinical Trial Site Sarasota Florida Recruiting
Clinical Trial Site Tamarac Florida Recruiting
Clinical Trial Site Shreveport Louisiana Recruiting
Clinical Trial Site Baltimore Maryland Recruiting
Clinical Trial Site Boston Massachusetts Recruiting
Clinical Trial Site New York New York Withdrawn
Clinical Trial Site Leland North Carolina Recruiting
Clinical Trial Site Cincinnati Ohio Recruiting
Clinical Trial Site Cleveland Ohio Recruiting
Clinical Trial Site Columbus Ohio Recruiting
Clinical Trial Site Pittsburgh Pennsylvania Recruiting
Clinical Trial Site Dallas Texas Recruiting
Clinical Trial Site Edinburg Texas Recruiting
Clinical Trial Site Salt Lake City Utah Recruiting
Clinical Trial Site Morgantown West Virginia Recruiting
Clinical Trial Site Norwich Norfolk Recruiting
Clinical Trial Site Leeds West Yorkshire Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07214311 on ClinicalTrials.gov ↗ ← All trials in the UK